CytomX Therapeutics Total Revenue

CytomX Therapeutics (CTMX) currently reports a total revenue of $18M as of June 2026. That compares with $140M in the prior-year period — down 87.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore CytomX Therapeutics's total revenue history and peer comparisons.

CytomX Therapeutics's total revenue decreased from $140M to $18M — a 87.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytomX Therapeutics's total revenue of $18M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

CytomX Therapeutics reported $18M in total revenue as of June 2026. That compares with $140M in the prior-year period — down 87.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for CytomX Therapeutics, and consider following CTMX for alerts when major investors trade the stock.